The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

bdsi.com

BioDelivery Sciences International has not claimed their Profile.

Want to better differentiate BioDelivery Sciences International between your competitors? Show buyers how.

Armgo Pharma company logo

Why does BioDelivery Sciences International win vs. Armgo Pharma?

Show BioDelivery Sciences International's primary competitive advantage

Show BioDelivery Sciences International's competitive differentiation

BioDelivery Sciences International's alternatives and competitors

See how BioDelivery Sciences International compares to similar products. BioDelivery Sciences International's top competitors include Armgo Pharma, Flexion Therapeutics, and EyePoint Pharmaceuticals.

Armgo Pharma is a biopharmaceutical company dedicated to the discovery and development of novel small-molecule therapeutics to treat debilitating cardiac, muscular, and…

BioDelivery Sciences International vs. Armgo Pharma

View more in-depth data on:

  • Competitors
  • Products
  • Customer References and more
  • Flexion Therapeutics discovers and develops therapeutics for musculoskeletal disorders. The company merges pharmacology with local, sustained delivery of drug to the si…

    BioDelivery Sciences International vs. Flexion Therapeutics

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • EyePoint Pharmaceuticals is a specialty biopharmaceutical company committed to developing and commercializing ophthalmic products.

    BioDelivery Sciences International vs. EyePoint Pharmaceuticals

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • Foamix Pharmaceuticals is a specialty pharmaceutical company, developing solutions for the field of dermatology. The company is in late-stage clinical development of tw…

    BioDelivery Sciences International vs. Foamix Pharmaceuticals

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • Genocea Biosciences is harnessing the power of T cell immunity to develop the next generation of vaccines. The company is working to create vaccines that stimulate the …

    BioDelivery Sciences International vs. Genocea Biosciences

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • Caliper Life Sciences (NASDAQ: CALP) is a research tools company engaged in the sale of new and enabling products, services, and systems to academic, government and an…

    BioDelivery Sciences International vs. Caliper Life Sciences

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is …

    BioDelivery Sciences International vs. Solidus Biosciences

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • RegeneMed, Inc. is accelerating the development of safer, more effective drugs by providing integrated high throughput platforms incorporating engineered human tissue-b…

    BioDelivery Sciences International vs. Regene Med

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • Transgenomic (NASDAQ:TBIO) is a global biotechnology company that advances personalized medicine in oncology and inherited diseases via its products and services for au…

    BioDelivery Sciences International vs. Transgenomic

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • Auxeris Therapeutics, Inc. is engaged in osteoporosis drug development

    BioDelivery Sciences International vs. Auxeris Therapeutics

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • was a technology developer in the fields of glycobiology and proteomics. Utilizing its technology, the company developed a lead pharmaceutical product Zavesca, that was…

    BioDelivery Sciences International vs. Oxford Glycosciences

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • Charles River Laboratories (NYSE: CRL) provides products and services to help pharmaceutical and biotechnology companies, government agencies, and leading academic inst…

    BioDelivery Sciences International vs. Charles River Laboratories

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • Cellogico Simulations Allow More Efficient Use Of Resources Through Highlighting Drug Targets With The Greatest Chance Of Success In The Early Stage Of Drug Development…

    BioDelivery Sciences International vs. Cellogico

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • The company's core business is and remains the development and production of Active Pharmaceutical Ingredient and parenteral formulations in the the form of solution an…

    BioDelivery Sciences International vs. Neon

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more

Work for BioDelivery Sciences International?

Brief our analysts.

Get in front of tech buyers.

100% free.

No pay-to-play nonsense.

You May Also Like

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

R
Regene Med

RegeneMed, Inc. is accelerating the development of safer, more effective drugs by providing integrated high throughput platforms incorporating engineered human tissue-based assays. RegeneMed possesses patented, proprietary, core technologies enabling the in vitro growth of engineered human tissues, including liver, GI tract, bone marrow and blood-brain barrier. These tissue-based in vitro model systems will accelerate drug development and aims to debottleneck ADME/Tox evaluation, the leading cause of drug failures facing the pharmaceutical industry, per the company.

Presage Biosciences Logo
Presage Biosciences

Presage Biosciences is an oncology company that focuses on evaluating patient response to drugs in clinical trials. The company uses CIVO technology to deliver pharmacologically appropriate concentrations of multiple drugs to different regions of a tumor – while the tumor is still in the patient.

N
Neon

The company's core business is and remains the development and production of Active Pharmaceutical Ingredient and parenteral formulations in the the form of solution and Lyophilized injection, in areas like anesthialogy and oncology.

O
Optimata

Optimata Ltd. is a privately-owned science-based interdisciplinary company engaged in biosimulation technology for optimizing drug treatment protocols. Optimata partners with pharmaceutical and biotechnology companies to develop effective new treatments for diseases by simulating disease processes. This aims to reduce time-to-market and development costs while improving the competitive profile of the newly developed drug.

N
NeuroGenomeX

NeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in animal models of traumatic brain injury (TBI).

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.